



SUPPORTED BY



Sixth International Conference on Novel Psychoactive Substances
8-9 April 2019
Maastricht, Netherlands

Programme

Conference website: www.novelpsychoactivesubstances.eu

#NPSMAASTRICHT

Venue: Maastricht University

Organising Committee

Ornella Corazza - University of Hertfordshire

Kim P.C. Kuypers - Maastricht University

Andres Roman-Urrestarazu - Maastricht University

Giuseppe Bersani – Sapienza University of Rome

Scientific Committee

Ornella Corazza (Chair) - University of Hertfordshire

Michael Evans-Brown - European Monitoring Centre for Drugs and Drug Addiction

Roumen Sedefov - European Monitoring Centre for Drugs and Drug Addiction

Ana Gallegos - European Monitoring Centre for Drugs and Drug Addiction

Olivier Rabin - World Anti-Doping Agency

Justice Tettey - United Nations Office on Drugs and Crime

Martin Raithelhuber - United Nations Office on Drugs and Crime

Fabrizio Schifano - University of Hertfordshire

Giovanni Martinotti - University of Chieti-Pescara

Giuseppe Bersani - Sapienza University of Rome

Andy Parrott - Swansea University

Francesco Botrè - Sapienza University of Rome

B.Vicknasingam, Centre for Drug Research - Universiti Sains Malaysia

Zsolt Demotrovics - Eötvös Loránd University

Sixth International Conference on Novel Psychoactive Substances

Over the last decade there has been a dramatic increase in the number of new psychoactive substances (NPS) detected in a growing number of countries worldwide. The NPS market continues to be highly dynamic and is characterized by the emergence of large numbers of new substances belonging to diverse chemical groups. Between 2009 and 2018, 119 countries and territories reported the emergence of 892 different NPS to UNODC, through the UNODC Early Warning Advisory on NPS. Overall, the EMCDDA, through the European Union Early Warning System, is monitoring more than 720 new psychoactive substances that have appeared since 1997. Of these, 90% have been reported in the last decade. The increase in the number and availability of NPS over the last few years has largely been driven by globalisation and technologies such as the Internet.

Yet recently there have been some encouraging signs, at least for Europe. For example, the number of new psychoactive substances reported for the first time has dropped from a high of almost 100 each year in 2015 to around 50 in 2016 — a trend that has continued in 2017 and 2018. In part this probably reflects the results of efforts to control NPS, especially their open sale in shops.

Nonetheless, NPS continue to cause numerous challenges. In Europe, at least one new substance is still detected every week, increasing the overall number that need to be monitored. Major new problems have also emerged, that have led to an increasing number and range of risks for people who use psychoactive substances. These include an increase in the number of highly potent NPS on the market, many of which are synthetic cannabinoids or synthetic opioids. These substances pose a high risk of life-threatening poisoning to users and are capable of causing serious outbreaks of adverse health events. Increasingly, users might also not be aware that they are using an NPS. Globalised supply chains and markets have also increased the opportunity for NPS (and a whole range of toxic chemicals) to be sold either deliberately or accidentally as other drugs, which can have deadly consequences. Related to this, stronger links also exist between the trade in NPS and markets in established controlled drugs: synthetic opioids may be sold as or mixed with heroin; new benzodiazepines are increasingly used to make fake medicines that are sold as diazepam and alprazolam; while cathinones, such as ephylone, may be sold as “ecstasy”.

Given the numerous challenges posed by new psychoactive substances — in terms of detection and identification, monitoring, understanding their use and the harms they cause, as well developing evidence-based public health responses — there is a need for multi-disciplinary and international collaboration to enhance knowledge and strengthen the quality of information sharing and good practices. The aim of the NPS conference series, now in its sixth edition, is to provide a forum that builds and strengthens such a collaboration to increase the evidence base on, and understanding of the nature and effects of NPS, as well as promote strategies to protect public health.

Key objectives

- Sharing evidence-based information on NPS and the latest trends in use.
- Support the development of early warning, preparedness and response activities to health and social harms caused by NPS.
- Exploring motivations and socio-cultural factors underlying NPS use.
- Improving understanding of clinical treatment and management of NPS use.
- Identifying public health implications of NPS.
- Improving understanding of prevention measures.
- Exploring policy and legislative responses to NPS.
- Networking and providing the opportunity to meet leading experts in the field.

TIMETABLE

Registration from 11:00	
Monday 8 April 2019 Welcome and opening remarks Location: FRANZ PALMZAAL	
13:00	<p>R. Sedefov European Monitoring Centre for Drugs and Drug Addiction</p> <p>J. Tetley United Nations Office on Drugs and Crime</p> <p>O. Corazza University of Hertfordshire, United Kingdom</p> <p>O. Rabin World Anti-Doping Agency</p> <p>J. Ramaekers Maastricht University, Netherlands</p>
Monday 8 April 2019 Plenary: Where are we with new psychoactive substances? Location: FRANZ PALMZAAL Moderator: O. Bowden Jones, Imperial College, United Kingdom	
13:15	<p>J. Tetley United Nations Office on Drugs and Crime The emergence of NPS - A crisis that did not happen?</p>
13:30	<p>M. Evans-Brown European Monitoring Centre for Drugs and Drug Addiction New psychoactive substances: A threat to health security</p>
13:45	<p>B. Logan Center for Forensic Science Research and Education, United States of America Ten years of NPS: Looking back and looking forwards</p>
14:00	<p>O. Corazza University of Hertfordshire, United Kingdom Learning from lived experiences</p>
14:15	<p>O. Rabin World Anti-Doping Agency NPS and sport: how we care about our athletes</p>
14:30	<p>M.J. Menendez Department of Justice, United States of America The call for science and law to unite against NPS</p>
14:45	Break & Networking

Monday 8 April 2019 Parallel Session 1: Use, settings, experiences, trends (1) Location: FRANZ PALMZAAL Moderator: A. Roman-Urrestarazu, Maastricht University, Netherlands	
15:00	E.D. Lockhart Drug Enforcement Administration, United States of America NPS trends in the US
15:15	A. Peacock University of New South Wales, Australia Trends in availability, use, and harms of NPS in Australia
15:30	A.U. Gil, S.P. Novikov, C.G. Palacio, R.A. Khalfin, S.A. Appolonova, S.A. Savchuk Sechenov First Moscow State Medical University, Russia The designer and synthetic drugs in the Khanty-Mansi autonomous region of Russia in 2017
15:45	R. Kikura-Hanajiri National Institute of Health Sciences, Japan An overview of recent emergence of NPS and their legal status in Japan
16:00	S.L. Kacinko, D.M. Papsun, B.K. Logan NMS Labs, United States of America NPS analysis and trends in the US: 2014-2018
16:15	Questions and discussion
16:30	Break – Coffee, Networking and Poster Session 1
Monday 8 April 2019 Parallel Session 2: Use, settings, experiences, trends (2) Location: FRANZ PALMZAAL Moderator: Fabrizio Schifano, University of Hertfordshire, United Kingdom	
16:50	D. Kappatos, M.J. McCarthy Institute of Environmental Science & Research, New Zealand AMB-FUBINACA and p-FPP: strange NPS bedfellows - a New Zealand context
17:05	A.L.A. Mohr, A.J. Krotulski, B.K. Logan Center for Forensic Science Research and Education, United States of America Identification of synthetic cannabinoid trends in forensic toxicology casework in the US using high resolution mass spectrometry
17:20	K.R. Burke Racine County Sheriff's Office, United States of America The trouble with the Standardized Field Sobriety Test in the US
17:35	B. Shapira, R. Berkovitz, P. Rosca, Y. Neumark Hebrew University of Jerusalem, Israel Recent use of synthetic cannabinoids, synthetic opioids and other psychoactive drug groups among a sample of high-risk drug users in Israel
17:50	A. Lloyd, R. Somerville, V. Hassan, E. Kolbe, C. Stansfield, H. Partington, K. Walsh, D. Kappatos, C. Johnson Institute of Environmental Science & Research, New Zealand A survey of synthetic cannabinoids in NZ street samples
18:05	R. Bade, J.M. White, J.F. Mueller, J. O'Brien, K.V. Thomas, B.J. Tschärke, C. Gerber University of South Australia, Australia Determining the occurrence of NPS in Australia using wastewater analysis
18:20	Questions and discussion

18:30	Close for the day
-------	-------------------

<p>Monday 8 April 2019 Parallel Session 3: Detection, identification, characterisation (1) Location: Seminar Room C-1.07 Moderator: I. Mazzoni, World Anti-Doping Agency</p>	
15:00	A. Guirguis, L. Calvo-Castro, E. Samaras, M. Zloh, S.B. Kirton, J.L. Stair University of Hertfordshire, United Kingdom Updates on the in-field detection of NPS
15:15	J.W. Lowdon, K. Eersels, B. Grinsven, T.J. Cleij Maastricht University, Netherlands Substrate displacement colorimetry for the detection of diarylethylamines
15:30	E.M. Guest Drug Enforcement Administration, United States of America Differentiating designer opioids U-48800 and U-51754 by GC/MSD
15:45	C. Chieffi, F. Botrè, C. Camuto, F. De Giorgio, X. de la Torre, M. Marti, C. Trapella, M. Mazzarino Italian Sports Medicine Federation, Italy The utility of in vitro metabolism studies coupled to liquid chromatography-tandem mass spectrometry for the selection of diagnostic markers of NPS: the case of 4,4'-DMAR
16:00	L. Anzillotti University of Parma, Italy Novel sampling-substrates for the determination of NPS in oral fluid by desorption electrospray ionization-high resolution mass spectrometry
16:15	Questions and discussion
16:30	Break – Coffee, Networking and Poster Session 1
<p>Monday 8 April 2019 Parallel Session 4: Detection, identification, characterisation (2) Location: Seminar Room C-1.07 Moderator: O. De Hon, Doping Authority, Netherlands</p>	
16:50	S.A. Savchuk, A.L. Petchnikov Sechenov First Moscow State Medical University, Russia Fast method for the preparation of cadaver tissue for GC-MS and HPLC-MS/MS analysis. Case study: Detection of carfentanyl in cadaveric tissues modified by rotting and in the products of tissue's lysis
17:05	T.B. Rodrigues, D.R. Morais, V.A.P. Gianvecchio, J.L. Costa University of Campinas, Brasil Development and validation of a method to analyze fentanyl and its analogs in post mortem blood samples by LC-MS/MS
17:20	E.O. Benchikh, P. Robinson, M.A. Gomez Randox Toxicology Ltd, United Kingdom The latest developments in New Psychoactive Substance Testing
17:35	N. Gilbert, L.H. Antonides, B. Kilkelly, C. Schofield, R.E. Mewis, O.B. Sutcliffe Manchester Metropolitan University, United Kingdom Hitting the Jackpot - Development of sensitive method for the routine screening of fentalogues within suspected samples of heroin

17:50	C. Guillou, J. Omar, B. Slowikowski, F. Reniero, M. Holland, A. Boix Joint Research Centre of the European Commission, Belgium Identification of NPS and in particular fentanyl analogs by Raman handheld spectroscopy
18:05	H. Gaspar, M. Sequeira, S. Santos, M.J. Caldeira University of Lisbon, Portugal Tracking NPS and amphetamines precursors in Portugal
18:20	Questions and discussion
18:30	Close for the day

Monday 8 April 2019

Parallel Session 5: Pharmacology and toxicology (1)

Location: Seminar Room C-1.05

Moderator: S. Assi, Liverpool John Moores University, United Kingdom

15:00	A. Rickli, K. Kolaczynska, M.C. Hoener, M.E. Liechti University of Basel, Switzerland Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR
15:15	L.H. Antonides, A. Cannaert, C. Norman, L.Vives, A. Harrison, N. NicDaeid, C., Stove, O.B. Sutcliffe, C. McKenzie University of Dundee, United Kingdom Enantiospecific synthesis, chiral separation and biological activity of four carboxamide-type synthetic cannabinoid receptor agonists and their detection in seized drug samples
15:30	L. Vasudevan, E. Wouters, A. Cannaert, M. Meyrath, M. Szpakowska, A. Chevigné, D.K. Saini, C.P. Stove Ghent University, Belgium Bioassays to study biased signaling of novel synthetic opioids
15:45	V. Abbate, O. Apirakkan, I. Gavrilovic, G. Floresta, C. Pierre, D. Cowan, L. Couchman King's College London, United Kingdom The interaction of synthetic cannabinoids and alcohol: an in-vitro evaluation
16:00	S.D. Banister, R.C. Kevin, I.S. McGregor, M. Glass, M. Connor, R. Gerona University of Sydney, Australia Emergent synthetic cannabinoid NPS and their prophetic analogues
16:15	Questions and discussion
16:30	Break – Coffee, Networking and Poster Session 1

Monday 8 April 2019

Parallel Session 6: Pharmacology and toxicology (2)

Location: Seminar Room C-1.05

Moderator: R. Kikura-Hanajiri, National Institute of Health Sciences, Japan

16:50	A. Weinstein University of Ariel, Israel Chronic use of synthetic cannabinoids (SCs) is associated with impairments in cognitive function, brain's structure and function, and comorbidity with depression and schizotypal personality disorder
17:05	A. Zwartsen Utrecht University, Netherlands Assessing reversibility of effects of acute and prolonged exposure to new psychoactive substances on neuronal activity in vitro to mimic human exposure

17:20	E.B. de Sousa Fernandes Perna, E.L. Theunissen, P.C. Dolder, N.L. Mason, N.R. Hutten, S.W. Toennes, K.P. Kuypers and J.G. Ramaekers Maastricht University, Netherlands Safety profile and neurocognitive function following acute 4-Fluoroamphetamine (4-FA) administration in humans
17:35	R.C. Kevin, L. Anderson, S.D. Banister, R. Boyd, C. Macdonald, M. Glass, M. Connor, I.S. McGregor University of Sydney, Australia CUMYL-4CN-BUTINACA: a potent synthetic cannabinoid receptor agonist with convulsant effects in mice
17:50	E.J. Kostic, B.B. Arsic, B.S. Milosavljevic, M.M. Vujovic University of Nis, Serbia Docking analysis of selected cathinones on a complex of SAP97 PDZ2 with 5-HT2A receptor peptide
18:05	J. Maier Medical University of Vienna, Austria The molecular mechanism of amphetamine-type stimulants
18:20	Questions and discussion
18:30	Close for the day

Monday 8 April 2019

Parallel Session 7: Prevention, harm reduction, treatment and clinical management (1)

Location: Seminar Room C-1.09

Moderator: M. Raithelhuber, United Nations Office on Drugs and Crime, Austria

15:00	S. Simonis, A. Van Dijck, L. Gremeaux, T. Van Havere, P. Blanckaert Scientific Institute of Public Health, Belgium Use and health needs regarding NPS: the users' perspective
15:15	A. Van Dijck, T. Van Havere, S. Simonis, P. Blanckaert, L. Gremeaux University College of Ghent, Belgium What are the needs of Belgian professionals for tackling the NPS phenomenon
15:30	K. MacLeod Scottish Drugs Forum, United Kingdom Treatment and information needs of vulnerable populations who use NPS
15:45	S. Bonaccorso, A. Metastasio, A. Ricciardi, N. Stewart, L. Jamal, N.U.D. Rujully, C. Theleritis, S. Ferracuti, G. Ducci, F. Schifano Camden and Islington NHS Foundation Trust, United Kingdom Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues
16:00	G. Martinotti University of Chieti-Pescara, Italy Substance-related exogenous psychosis: a novel form of psychopathology induced by NPS
16:15	Questions and discussion
16:30	Break – Coffee, Networking and Poster Session 1

Monday 8 April 2019

Parallel Session 8: Prevention, harm reduction, treatment and clinical management (2)

Location: Seminar Room C-1.09

Moderator: G. Bersani, Sapienza University of Rome, Italy

16:50	A. Metastasio, S. Bonaccorso, A. Kwan Camden and Islington NHS Foundation Trust, United Kingdom Management of inpatients using NPS
17:05	Q. Abbas Government College University Faisalabad, Pakistan Cognitive behavior therapy with opioid use disorder: a case study
17:20	K. MacLeod Scottish Drugs Forum, United Kingdom NPS related mental health presentations in United Kingdom festivals
17:35	S. Marrinan University of Hertfordshire, United Kingdom Mandatory drug testing in prison settings - helpful, or harmful?
17:50	R. Vaziri, M. Hallam, L. Wilson Humankind, United Kingdom A novel and evolving response to emergency situations: experience from the largest integrated drugs & alcohol service in England
18:05	F. Mucci University of Pisa, Italy Problematic internet use: preliminary data on prevalence in Italian public rehab centers
18:20	Questions and discussion
18:30	Close for the day

Monday 8 April 2019

Parallel Session 9: Performance and image enhancing drugs (1)

Location: Seminar Room C-1.03

Moderator: A. Petroczi, Kingston University, United Kingdom

15:00	D. Sagoe, C.S. Andreassen, S. Pallesen University of Bergen, Norway Pathways to anabolic steroid use: a systematic review and meta-synthesis
15:15	S. Odoardi, S. Mestria, V. Valentini, S. Strano Rossi Università Cattolica del Sacro Cuore, Italy The black market of PIEDs in Italy
15:30	M.D. Chandler University of Birmingham, United Kingdom Peptide hormones and SARMs - the "new wave" of PIEDs
15:45	T. Knox University of Birmingham, United Kingdom Routes of testosterone administration amongst female PIED users
16:00	R. Heyes University of Birmingham, United Kingdom Psychosocial factors facilitating use of cognitive enhancing drugs in education: a qualitative investigation of moral disengagement and associated processes
16:15	Questions and discussion
16:30	Break – Coffee, Networking and Poster Session 1

Monday 8 April 2019

Parallel Session 10: Performance and image enhancing drugs (2)

Location: Seminar Room C-1.03	
Moderator: I. Boardley, University of Birmingham, United Kingdom	
16:50	A. Petroczi, J. Shelley, A. Hudson Kingston University London, United Kingdom "Play Safe!" - Practical risk-assessment framework for PIEDs
17:05	R. Cunningham, B. Fincoeur, F. Ohl University of Lausanne, Switzerland Organisational factors, identity and precariousness in elite cycling
17:20	A. Avdagic, N. Ahmetovic Agency for Antidoping Control, Bosnia and Herzegovina The status and perspectives of the fight against doping in sport in Bosnia and Herzegovina with the focus on NPS
17:35	P. Simonato, Z. Demetrovics, K. van de Ven, G. Martinotti, O. Corazza Dual-Diagnosis Unit, Clinic Parco dei Tigli, Italy The health risks of looking fit. Supplement use, appearance anxiety and exercise addiction
17:50	B. Fincoeur, F. Ohl University of Lausanne, Switzerland On performance-enhancing drugs use by mixed martial arts athletes
18:05	Questions and discussion
18:30	Close for the day

Tuesday 9 April 2019	
Parallel Session 11: Early-warning and toxicovigilance	
Location: Seminar Room C-1.03	
Moderator: F. Botré, Sapienza University of Rome, Italy	
9:00	A. Gallegos EMCDDA Update from the European Union Early Warning System
9:15	L. Hondebrink, J.J. Nugteren-van Lonkhuyzen, I.S. van den Hengel-Koot, S.J. Rietjens, A.J.H.P. van Riel Utrecht University, Netherlands NPS exposures reported to the Dutch Poisons Information Center
9:30	P. Blanckaert, J. Antoine, E. Plettinckx, S. Simonis, L. Van Baelen, L. Gremeaux Belgian Early Warning System Drugs, Belgium Deaths caused by NPS opioids in Belgium
9:45	J. Grigg, R. Crossin, J. Killian, S. Arunogiri, S. Matthews, D. Scott, V. Manning, D. Taylor, K. Smith, D.I. Lubman Monash University, Australia Recent trends in synthetic cannabinoid use in Australia resulting in ambulance attendance
10:00	M.J. McCarthy Institute of Environmental Science & Research, New Zealand Managing NPS in New Zealand: a "Border to Grave" approach
10:15	Questions and discussion
10:30	Break – Coffee, Networking and Poster Session 2
Tuesday 9 April 2019	
Parallel Session 12: Monitoring NPS	
Location: Seminar Room C-1.03	

Moderator: D. Singh, Centre for Drug Research, Universiti Sains Malaysia, Malaysia	
11:00	D. van der Gouwe Trimbos Institute, Netherlands Monitoring NPS in the Netherlands: combining data from various sources
11:15	A. Lloyd, K. Nguyen Institute of Environmental Science & Research, New Zealand Dark web drug monitoring
11:30	M. Mignone, E. Bosio, V. Scioneri Research Center on Security and Crime, Italy Illegal drug trafficking on the darkweb: key findings from a cross-sectional study on a sample of cryptomarkets
11:45	D. Rhumorbarbe, M. Morelato, L. Staehli, C. Roux, D.O. Jaquet-Chiffelle, Q. Rossy, J. Tettey, M. Raithelhuber, P. Esseiva University of Lausanne, Switzerland The systematic analysis of drug discussion forums and cryptomarkets: is it useful to monitor NPS?
12:00	F. Béen, E. Emke, T. ter Laak, P. de Voogt KWR Watercycle Research Institute, Netherlands Advancing wastewater-based epidemiology towards a comprehensive community-wide monitoring and early-warning system
12:15	M. Blankers, D. van der Gouwe, M. van Laar Trimbos Institute, Netherlands 4-Fluoramphetamine in the Netherlands: text mining and sentiment analysis of internet fora
12:30	Questions and discussion
13:00	Break – Lunch, Networking and Poster Session 3

Tuesday 9 April 2019	
Parallel Session 13: Use, settings, experiences, and trends (3)	
Location: Seminar Room C-1.05	
Moderator: S. Bonaccorso, Camden and Islington NHS Foundation Trust, United Kingdom	
9:00	L.A. Lione, E. Deligianni, O.J. Daniel, J.M. Corkery, F. Schifano University of Hertfordshire, United Kingdom NPS awareness, use, preference and health perception following the United Kingdom Psychoactive Substances Act 2016
9:15	J. Neicun, J.C. Yang, H. Shih, R. van Kessel, A. Negri, P. Nadella, K. Czabanowska, O. Corazza, C. Brayne, A. Roman-Urrestarazu University of Hertfordshire, United Kingdom Lifetime prevalence of NPS among the general population in the US from 2007-2014
9:30	M.M. Vujovic, B.S. Milosavljevic, E.J. Kostic, M.M. Djukic University of Nis, Serbia Annual (2018) substance abuse research report in South-East Serbia according toxicology data of forensic institute in Nis
9:45	M. Farré, E. Olesti, R. de la Torre, M. Ventura, L. Poyatos, C. Pérez-Mañá, M. Torrens, E. Papaseit Universitat Autònoma de Barcelona, Spain An observational study of the acute effects of two synthetic cathinones: mephedrone and methylone

10:00	F. Morgante Middlesex University, United Kingdom Ayahuasca use: potential benefits and harm reduction
10:15	Questions and discussion
10:30	Break – Coffee, Networking and Poster Session 2
Tuesday 9 April 2019 Parallel Session 14: Use, settings, experiences, and trends (4) Location: Seminar Room C-1.05 Moderator: F.S. Bersani, Sapienza University of Rome, Italy	
11:00	S. Assi, T. Coombs, T. Ginige, P. Van Calster, C. Devany, J. McEachran, O. Corazza Bournemouth University, United Kingdom Prevalence, effects and toxicity of NPS from the perspectives of the homeless population
11:15	K.J. Stockdale, M. Addison York St. John University, United Kingdom Exploring NPS and custodial environments
11:30	H. Claridge, C.M. Goodair St George's University of London, United Kingdom Fentanyl fatalities in England, 1998-2018
11:45	J.M. Corkery University of Hertfordshire, United Kingdom Synthetic cathinones and related fatalities in the United Kingdom
12:00	E. Emke, L. Bijlsma, A. Celma, D. Vughs, K. Hup, P. de Voogt KWR Watercycle Research Institute, Netherlands The use of wastewater-based epidemiology to qualify and quantify NPS use during an electronic dance festival
12:15	M. Vigar G4S Care & Justices Services, United Kingdom NPS in United Kingdom prisons
12:30	A. Salomone, M. Vincenti University of Turin, Italy Should the NPS be included in workplace drug testing?
12:45	Questions and discussion
13:00	Break – Lunch, Networking and Poster Session 3

Tuesday 9 April 2019 Parallel Session 15: Pharmacology and toxicology (3) Location: Seminar Room C-1.09 Moderator: K.P.C. Kuypers, Maastricht University, Netherlands	
9:00	E.L. Theunissen, N.R.P.W. Hutten, N.L. Mason, S.W. Toennes, K.P.C. Kuypers, J.G. Ramaekers Maastricht University, Netherlands Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: responders versus non-responders
9:15	C. Lehmann, R. Kegler, D. Rentsch, J. Manhart, A. Büttner Brandenburg Institute for Forensic Medicine, Germany Health hazards after using the synthetic cannabinoid 5F-ADB

9:30	E. Pottie, A. Cannaert, C.P. Stove Ghent University, Belgium Development and application of an activity-based bio-assay for the profiling of hallucinogenic NPS
9:45	S. Chiappini, A. Guirguis, J.M. Corkery, F. Schifano University of Hertfordshire, United Kingdom Prescription and over-the-counter drug misuse in the context of the NPS scenario; considering the pharmacovigilance approach to evaluate the abuse and misuse of medications
10:00	E. Wouters, L. Mogler, A. Cannaert, V. Auwärter, C. Stove Ghent University, Belgium Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on valine or tert-leucine
10:15	Questions and discussion
10:30	Break – Coffee, Networking and Poster Session 2
Tuesday 9 April 2019 Parallel Session 16: Policy and legislation Location: Seminar Room C-1.09 Moderator: J. Collins, London School of Economics, United Kingdom	
11:00	B. Byrska, R. Stanaszek, W. Wrzesień, D. Zuba Institute of Forensic Research, Poland Prevalence of NPS on the Polish drug market after the 1st of July 2015
11:15	L.L. Wong, M.L. VanLinn, T.L. Boos Drug Enforcement Administration, United States of America NPS trends and controls in the US
11:30	R. Kühnl, S. Horn, L. Kraus IFT Institute for Therapy Research Munich, Germany Introduction of the New Psychoactive Substances Act in Germany: perceived changes and opinions of persons affected by the law
11:45	<i>Hardy S., Brown M., Comber L.</i> International Drug Policy, Home Office, United Kingdom Review of the United Kingdom Psychoactive Substances Act
12:00	R.M. Souza, L.S. Lopes, G.H. Giudice, G.M.O. Latuf, M.L.S. Macedo, L.F. Machado, E.S. Santana, S.R.S.C. Souza Brazilian National Health Regulatory Agency, Brazil Generic classification for synthetic cannabinoids as controlled substances in Brazil
12:15	A.T.W. Yap, W.J.L. Lim, M.C. Ong Health Science Authority, Singapore Strategies and collaboration to counter the NPS challenge
12:30	D. Kumpe Department of Health, Welfare and Sport, Netherlands Legal situation of NPS in the Netherlands
12:45	E. Liberska, K. Juško Bureau for Chemical Substances in Lodz, Poland NPS in Poland – policy and legislation
13:00	Break – Lunch, Networking and Poster Session 3

Tuesday 9 April 2019

Closing Session: Where next for new psychoactive substances?

Location: FRANZ PALMZAAL Moderator: R. Sedefov, EMCDDA	
14:00	Panel and audience discussion: B. Logan, M.J. Menendez, O. Corazza, M. Evans-Brown, K. MacLeod, R. Vaziri and O. Bowden Jones
15:00	Closing remarks
15:15	Evaluation
15:30	Close of the conference

POSTER PRESENTATIONS

	SESSION 1 Monday 8 April 2019 (16.30-16:50) Location: Ad Fundum Coordinator: D. Collins, Middlesex University, United Kingdom
1	I.S. van den Hengel-Koot, D. van der Gouwe, J.J. Nugteren-van Lonkhuyzen, S.J. Rietjens, A.J.H.P. van Riel, L. Hondebrink Dutch Poisons Information Center, University Medical Center Utrecht, Netherlands “4-Fluoroamphetamine (4-FA): before and after legislation”
2	M. Schläpfer, C. Bissig Zurich Forensic Science Institute, Switzerland “A group listing for fentanyls in the narcotics regulation”
3	F. De-Giorgio, S. Bilel, A. Ossato, R. Arfè, M. Tirri, F. Foti, G. Serpelloni, P. Frisoni, M. Neri, M. Marti Catholic University of Sacred Heart, Italy “Acute and repeated administration of MDPV increases aggressive behaviour in mice: forensic Implications”
4	J.J. Nugteren - van Lonkhuyzen, L. Hondebrink, I.S. van den Hengel-Koot, S.J. Rietjens, B. Venhuis, A.J.H.P. van Riel Dutch Poisons Information Center, University Medical Center Utrecht, Netherlands “Alpha-PVP: a media hype?”
5	G. Mercieca, S. Odoardi, M. Cassar, S. Strano Rossi BioDNA laboratory services, Malta “Application of ultrasound assisted dispersive liquid-liquid micro extraction coupled with GC-MS for the rapid determination of synthetic cannabinoids and metabolites in biological samples”
6	L.N. Caldas, J.J. Zacca, A.O. Maldaner, M.L. Vieira, E.D. Botelho, J.N. Serrano, A.L. Oliveira, M.P. Souza National Institute of Criminalistics, Brazil “Challenges in the identification of New Thermolabile Psychoactive Substances: the 25I-NBOH Case”
7	R. Vaziri, M. Hallam Humankind, United Kingdom “Climbing a mountain with no guide ropes – when there are no guidelines... NPS withdrawal and detoxification what do you do?”
8	K.M. Shestakova, S.A. Savchuk, S.A. Appolonova Sechenov First Medical University, Russia

	“Development of a new screening method for determination of illegal drugs including NPS and their metabolites in urine by means of UPLC- MS/MS”
9	M.L.S. Macedo, L.C. Arantes, R. Bonach, R.P.A. Cruz, G.H. Giudice, L.S. Lopes, L.F. Machado, C.B.C. Passos, E.S. Santana, I.R.C. Silva, M.P. Souza, R.M. Souza, S.R.S.C. Souza. Brazilian Health Regulatory Agency, Brazil “Elaboration of Generic Legislation for Synthetic Cathinones in Brazil”
10	K.F. Cunha, K.D. Oliveira; J.L. Costa University of Campinas, Brazil “Evaluation of New Psychoactive Substances abuse in Brazil by the analysis of oral fluid samples”
11	T. Coombs, P. Van Calster, C. Devany, T. Ginige, J. McEachran, O. Corazza, S. Assi Bournemouth University, United Kingdom “Exploring the experience of NPS among users from the homeless population: a pilot study”
12	R.M. Souza Brazilian National Health Regulatory Agency, Brazil “Generic classification for synthetic cannabinoids as controlled substances in Brazil”
13	S. Strano Rossi, S. Odoardi, S. Mestria, F. Zancanaro, L. Zamengo, G. Frison University Cattolica del Sacro Cuore, Rome, Italy “High resolution/high accuracy mass spectrometry for the identification of illicit substances sold in the black market”
14	L. Rizvanova, S. Savchuk Nizhnevartovsk Psychoneurological Hospital, Russia “Identification of psychoactive substances and their metabolites in human urine, blood, hair and nails in case of combined use of ADB-FUBINACA and alpha-PVP”
	SESSION 2 Tuesday 9 April 2019 (10.30-11:00) Location: Ad Fundum Coordinator: V. Catalani, University of Hertfordshire, United Kingdom
15	R. Tanaka, M. Kawamura, T. Hakamatsuka, R. Kikura-Hanajiri National Institute of Health Sciences, Japan “Identification of five tryptamine derivatives in illegal products in Japan”
16	P.M. Verputten, S.J. Rietjens, I.S. van den Hengel - Koot, R.R. Contrucci, J.J. Nugteren - van Lonkhuyzen, D.W. de Lange, L. Hondebrink Utrecht University, Netherlands “Injection of cathinones: exposures reported to the Dutch Poisons Information Center”
17	J.M. Eassey, J.M. Stogner, B.M. Miller, and J.M. Baldwin American University, United States of America “Investigating NPS Use among LGBTQ Adolescents in the U.S.”
18	M. Mazzarino, C. Camuto, F. De-Giorgio, X. de la Torre, M. Marti, S. Samperi, F. Botrè Italian Sports Medicine Federation, Italy “In vitro characterization of the metabolic pathways of four new synthetic cannabinoids”
19	S. Chiappini, F. Schifano, A. Guirguis, J.M. Corkery School of Life and Medical Sciences, University of Hertfordshire, United Kingdom “Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports”
20	B. Federico, G. Capelli, B. Palumbo, P.W. Gabriele World Bridge Federation Medical and Prevention Commission, Switzerland “Knowledge and attitudes towards the use of cognitive performance enhancers of young elite Bridge players”

21	M.A. Gofenberg, V.A. Shevyrin Sverdlovsk Regional Poison Treatment Centre, Russia “Laboratory diagnostics of acute poisoning with 3,4-methylenedioxy- α -pyrrolidinohexanophenone (3,4-MDPHP) in the Sverdlovsk region”
22	J. Mead, A. Parrott Swansea University, United Kingdom “Mephedrone and MDMA: a comparative review”
23	C. Camuto, S. Bilel, A. Ossato, M. Tirri, R. Arfè, A. Fantinati, F. Foti, M. Neri, X. de la Torre, M. Mazzarino, F. Botrè, F. De-Giorgio, M. Marti Catholic University of Sacred Heart, Italy “Metabolic profile and pharmaco-toxicological effects of MPA in mouse model.”
24	H. Kettner, N.L. Mason, K.P.C. Kuypers Maastricht University, Netherlands “Motives for classical and NPS use of psychedelic polydrug-users”
25	S.A. Savchuk, N.M. Nikitina, C. Palacio, S. Appolonova, F. Tagliaro Sechenov First Medical University, Russia “New GC-MS approach for detection of general anesthetics in complex biological matrices. Detection of Carfentanyl in putrefied tissue, a case study”
26	A.R. Bohara Nepal Police, Narcotics Control Bureau, Nepal “NPS in Nepal and role of Law Enforcement Officials”
27	S.H. Zhang Health Sciences Authority, Singapore “New Psychoactive Substances in “Stamps””
28	A. Lloyd, C. Johnson, B. Copp, A. Lewis Institute of Environmental Science & Research Ltd (ESR), New Zealand “NPS seized at the New Zealand border”
	SESSION 3 Tuesday 9 April 2019 (13:30-14:00) Location: Ad Fundum Coordinator: Attilio Negri, University of Milan, Italy
29	S. Coloccini, S. Marrinan, A. Negri, A. Metastasio, G. Bersani, O. Corazza Sapienza University of Rome, Italy “NPS in prisons: a study on the challenge faced by health and non-health professionals working in acute and restricted mental health settings”
30	X. Rego, J. Pereira APDES, Portugal “Offline and online drug markets: social meanings ascribed to different ways of accessing drugs”
31	N.M. Nikitina, S.A. Savchuk Pskov Regional Narcological Dispensary, Russia “Optimization possibilities of chemical- toxicological analysis using GC-MS and HPLC-MS-MS methods”
32	E.B. Pipina Russia “Practical cases: practical combined poisoning with fentanyl and other narcotic substances”
33	D. Singh University Sains, Malaysia “Prevalence of side-effects in Opioid and Kratom (<i>Mitragyna speciosa</i> Korth) Use”

34	E. Levari, A. Lotti, M. Frenguelli, V. Longo, M. Gottardi, M. Marchio, M. Stefani, R. Ferrucci, A. Negri, O. Corazza Trento Addiction Unit, Italy "Searching for synthetic opioids on keratin matrix"
35	M.M. Hasan, N.I. Sikder Ministry of Home Affairs, Department of Narcotics Control, Bangladesh "Sharing evidence-based information on NPS and exploring policy and legislative responses to them in Bangladesh"
36	N.L. Mason, E.M. Mischler, M.V. Uthaug, K.P.C. Kuypers Maastricht University, Netherlands "Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being"
37	A. Lopez Larkin University, USA "Substituted phenethylamine associated mortality: Results of a retrospective review of regional medical examiner cases from 2014-2017"
38	M. Stefani, E. Levari, R. Ferrucci, O. Corazza Trento Addiction Unit, Italy "The abuse of opioid analgesics: a clinical case study"
39	K.H. Kang, M.R. Ke, W.T. Chen, J. Hsu, W.I. Tsay National Health Research Institute, Taiwan "The current prevalence of NPS in Taiwan"
40	J. O'Keeffe New Zealand's National Drug Intelligence Bureau The New Zealand's Drug Early Warning System
41	K.J. Siefried, A. Peacock, N. Ezard National Centre for Clinical Research on Emerging Drugs, Australia "Towards a prompt response network for Australia: coordinated and rapid communication of information about events of concerns related to emerging substances"
42	V. Suresh, T.C. Tanwar Customs Laboratory, India "Trends/control of NPS – Indian scenario"
43	M.V. Prilutskaya Semey Medical University, Kazakhstan "Unravelling the novelty or what kind of the NPS dynamics has experienced Kazakhstan?"